Status:

TERMINATED

A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives

Lead Sponsor:

University of Mississippi Medical Center

Conditions:

Obesity

Hypertension

Eligibility:

All Genders

21-100 years

Phase:

NA

Brief Summary

Obesity and hypertension are independent risks for congestive heart failure (CHF) and chronic kidney disease. In obesity induced hypertension, the most common cause of human essential hypertension, th...

Detailed Description

The proposed trial will utilize an open label study design. Patients with hypertension and obesity will be recruited. After a 3-week washout period for patients currently on antihypertensive medicatio...

Eligibility Criteria

Inclusion

  • Systolic blood pressure (SBP) between 140 and 160 mmHg and/or a diastolic blood pressure between 90 and 100 mmHg who also have a body mass index \> 30-45.
  • Women must be post menopausal

Exclusion

  • Women of child bearing potential
  • BMI less than 30 or greater than 45
  • A creatinine \> 1.8 for females and \> 2.0 for males
  • Type 1 or type 2 diabetes
  • Current evidence of alcohol or drug abuse problems

Key Trial Info

Start Date :

January 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2014

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT00825188

Start Date

January 1 2009

End Date

March 1 2014

Last Update

May 29 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The University of Mississippi Clinical Research Program

Jackson, Mississippi, United States, 39216

A Study of the Effects of Eplerenone and Amlodipine on Blood Pressure and Basal Metabolic Rate in Obese Hypertensives | DecenTrialz